Related Experiment Videos
Rediscovering hydroxyurea: its role in recalcitrant psoriasis
1Department of Dermatology, Venereology and Leprology, Postgraduate Institute of Medical Education and Research, Chandigarh 160012, India. kumarbhushan@hotmail.com
International Journal of Dermatology
|November 13, 2001
Summary
Hydroxyurea effectively treats extensive chronic plaque psoriasis (CPP) with minimal side effects. This study shows it
Area of Science:
- Dermatology
- Pharmacology
Background:
- Limited second-line systemic treatment options for extensive chronic plaque psoriasis (CPP).
- Renewed interest in hydroxyurea due to recent safety and dosage data in other conditions.
Purpose of the Study:
- To evaluate the efficacy and tolerability of hydroxyurea in patients with extensive CPP.
- To assess hydroxyurea as a second-line treatment for patients unable to use first-line oral agents.
Main Methods:
- Prospective, nonrandomized study of 31 patients with extensive CPP.
- Hydroxyurea administered at 1-1.5 g daily for a median of 36 weeks.
- Patients followed for an average of 36.1 weeks.
Main Results:
- Nearly 75% of patients achieved adequate response (≥35% PASI reduction within 8 weeks).
- Over 50% experienced >70% reduction in Psoriasis Area and Severity Index (PASI) score.
- All adverse effects were mild, reversible, and did not necessitate treatment cessation.
Conclusions:
- Hydroxyurea demonstrates efficacy and safety as a second-line treatment for extensive CPP.
- It offers a slower-acting but effective alternative for short-to-medium term management.
- The drug is well-tolerated, with no patients discontinuing therapy due to side effects.